By flow cytometry we validated the higher expression of Slamf6, a key Tpex marker, in sgElovl1 OT-I T cells infiltrating anti-PD-1-treated tumours compared with control groups (Extended Data Fig. 3d). Here, SLAMF6 is linked to neoplasm.